Table 1.
Antiproliferative activities of protein samples against four tumor cell lines (IC50, μg/mL ± SD, n = 3).
| IC50 (µg/mL) | ||||
|---|---|---|---|---|
| HT-29 | HepG2 | HeLa | A549 | |
| L1 | 418.2 ± 122.1 | >500 | >500 | >500 |
| V2 | 490.9 ± 161.0 | >500 | >500 | >500 |
| V3 | 461.7 ± 212.4 | >500 | >500 | >500 |
| J3-1 | 346.2 ± 43.0 | 497.2 ± 74.3 | 494.2 ± 81.9 | 407.7 ± 63.5 |
| D1 | >500 | >500 | >500 | >500 |
| D2 | 154.8 ± 12.6 | 422.1 ± 32.7 | 480.6 ± 22.5 | 366.8 ± 41.7 |
| D3 | 222.9 ± 42.2 | >500 | >500 | >500 |
| D2-1 | >500 | >500 | >500 | >500 |
| D2-2 | 83.7 ± 19.6 | >500 | >500 | >500 |
| D2-3 | 25.4 ± 1.2 | 281.0 ± 19.8 | 271.3 ± 15.1 | 235.2 ± 20.5 |
| Cisplatin | 7.59 ± 0.09 | 3.22 ± 0.02 | 1.56 ± 0.08 | 0.79 ± 0.05 |
Fraction L1: The supernatant after homogenate; Fraction V2: The precipitate after 0%–35%; (NH4)2SO4 saturation; Fraction V3: The precipitate after 35%–70% (NH4)2SO4 saturation; Fraction J3-1: The precipitate after 70%–100% (NH4)2SO4 saturation.